(Q38020739)

27 August 2017

title

Apixaban: a novel oral inhibitor of factor Xa. (English)

1 reference

27 August 2017

1 reference

Edith Nutescu

1

1 reference

27 August 2017

publication date

1 July 2012

1 reference

American Journal of Health-System Pharmacy

27 August 2017

published in

1 reference

27 August 2017

volume

69

1 reference

27 August 2017

issue

13

1 reference

27 August 2017

page(s)

1113-1126

1 reference

The Worcester Venous Thromboembolism study: a population-based study of the clinical epidemiology of venous thromboembolism

27 August 2017

cites work

1 reference

https://api.crossref.org/works/10.2146%2FAJHP110418

Epidemiology and predictors of short-term mortality in symptomatic venous thromboembolism.

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP110418

Executive Summary: Heart Disease and Stroke Statistics—2010 Update

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP110418

Atrial fibrillation is a major risk factor for stroke, especially in women: the Jichi Medical School cohort study

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP110418

Upper-extremity deep vein thrombosis

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP110418

New oral anticoagulants in development

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP110418

The new oral anticoagulants

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP110418

New anticoagulants for treatment of venous thromboembolism

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP110418

Patterns of use of antithrombotic therapy and quality of anticoagulation among patients with non-valvular atrial fibrillation in clinical practice

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP110418

Advanced age, anticoagulation intensity, and risk for intracranial hemorrhage among patients taking warfarin for atrial fibrillation

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP110418

Benefit of oral anticoagulant over antiplatelet therapy in atrial fibrillation depends on the quality of international normalized ratio control achieved by centers and countries as measured by time in therapeutic range

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP110418

The influence of oral anticoagulation therapy on deep vein thrombosis rates four weeks after total hip replacement.

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP110418

Discovery of 1-(4-methoxyphenyl)-7-oxo-6-(4-(2-oxopiperidin-1-yl)phenyl)-4,5,6,7-tetrahydro-1H-pyrazolo[3,4-c]pyridine-3-carboxamide (apixaban, BMS-562247), a highly potent, selective, efficacious, and orally bioavailable inhibitor of blood [...]

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP110418

Apixaban, an oral direct factor Xa inhibitor, inhibits human clot-bound factor Xa activity in vitro.

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP110418

Apixaban, an oral, direct and highly selective factor Xa inhibitor: in vitro, antithrombotic and antihemostatic studies

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP110418

Favorable therapeutic index of the direct factor Xa inhibitors, apixaban and rivaroxaban, compared with the thrombin inhibitor dabigatran in rabbits.

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP110418

Arterial antithrombotic and bleeding time effects of apixaban, a direct factor Xa inhibitor, in combination with antiplatelet therapy in rabbits

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP110418

Clinical laboratory measurement of direct factor Xa inhibitors: anti-Xa assay is preferable to prothrombin time assay

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP110418

Dabigatran etexilate--a novel, reversible, oral direct thrombin inhibitor: interpretation of coagulation assays and reversal of anticoagulant activity

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP110418

Apixaban metabolism and pharmacokinetics after oral administration to humans

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP110418

Comparative metabolism of 14C-labeled apixaban in mice, rats, rabbits, dogs, and humans.

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP110418

In vitro assessment of metabolic drug-drug interaction potential of apixaban through cytochrome P450 phenotyping, inhibition, and induction studies

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP110418

Apixaban, an oral, direct, selective factor Xa inhibitor, in combination with antiplatelet therapy after acute coronary syndrome: results of the Apixaban for Prevention of Acute Ischemic and Safety Events (APPRAISE) trial.

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP110418

The efficacy and safety of apixaban, an oral, direct factor Xa inhibitor, as thromboprophylaxis in patients following total knee replacement.

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP110418

Quantification of apixaban's therapeutic utility in prevention of venous thromboembolism: selection of phase III trial dose

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP110418

Apixaban or enoxaparin for thromboprophylaxis after knee replacement

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP110418

Apixaban versus enoxaparin for thromboprophylaxis after knee replacement (ADVANCE-2): a randomised double-blind trial

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP110418

Apixaban versus enoxaparin for thromboprophylaxis after hip replacement

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP110418

Venous thromboembolism risk and prophylaxis in the acute hospital care setting (ENDORSE study): a multinational cross-sectional study

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP110418

Venous thromboembolism in acutely ill hospitalized medical patients

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP110418

Prevention of venous thromboembolism: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition)

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP110418

Extended-duration venous thromboembolism prophylaxis in acutely ill medical patients with recently reduced mobility: a randomized trial

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP110418

Apixaban versus enoxaparin for thromboprophylaxis in medically ill patients

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP110418

Apixaban versus warfarin in patients with atrial fibrillation

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP110418

Antithrombotic therapy for venous thromboembolic disease: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition).

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP110418

Efficacy and safety of the oral direct factor Xa inhibitor apixaban for symptomatic deep vein thrombosis. The Botticelli DVT dose-ranging study

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP110418

Aspirin: promise and resistance in the new millennium

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP110418

ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation: full text: A report of the American College of Cardiology/American Heart Association Task Force on practice guidelines and the European Society of Cardiology Committ

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP110418

Rationale and design of AVERROES: apixaban versus acetylsalicylic acid to prevent stroke in atrial fibrillation patients who have failed or are unsuitable for vitamin K antagonist treatment

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP110418

Apixaban in patients with atrial fibrillation

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP110418

Apixaban for reduction in stroke and other ThromboemboLic events in atrial fibrillation (ARISTOTLE) trial: design and rationale

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP110418

Combined antiplatelet and anticoagulant therapy: clinical benefits and risks

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP110418

Effectiveness and safety of combined antiplatelet and anticoagulant therapy: a critical review of the evidence from randomized controlled trials

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP110418

Apixaban with antiplatelet therapy after acute coronary syndrome

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP110418

Effect of apixaban, an oral and direct factor Xa inhibitor, on coagulation activity biomarkers following acute coronary syndrome

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP110418

Safety, pharmacodynamics, and pharmacokinetics of BAY 59-7939--an oral, direct Factor Xa inhibitor--after multiple dosing in healthy male subjects

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP110418

Dose-escalation study of the pharmacokinetics and pharmacodynamics of rivaroxaban in healthy elderly subjects

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP110418

The pharmacokinetics, pharmacodynamics and tolerability of dabigatran etexilate, a new oral direct thrombin inhibitor, in healthy male subjects

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP110418

Pharmacokinetics and pharmacodynamics of the direct oral thrombin inhibitor dabigatran in healthy elderly subjects

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP110418

Metabolism and excretion of rivaroxaban, an oral, direct factor Xa inhibitor, in rats, dogs, and humans

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP110418

Comparative pharmacodynamics and pharmacokinetics of oral direct thrombin and factor xa inhibitors in development

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP110418

Dabigatran versus warfarin in patients with atrial fibrillation

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP110418

Rivaroxaban versus warfarin in nonvalvular atrial fibrillation

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP110418

Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty (RECORD4): a randomised trial

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP110418

Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP110418

Extended duration rivaroxaban versus short-term enoxaparin for the prevention of venous thromboembolism after total hip arthroplasty: a double-blind, randomised controlled trial

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP110418

Rivaroxaban versus enoxaparin for thromboprophylaxis after hip arthroplasty

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP110418

Oral rivaroxaban for the prevention of symptomatic venous thromboembolism after elective hip and knee replacement

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP110418

Rivaroxaban vs dabigatran for thromboprophylaxis after joint-replacement surgery: exploratory indirect comparison based on meta-analysis of pivotal clinical trials

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP110418

Enoxaparin versus dabigatran or rivaroxaban for thromboprophylaxis after hip or knee arthroplasty: Results of separate pooled analyses of phase III multicenter randomized trials

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP110418

Oral thrombin inhibitor dabigatran etexilate vs North American enoxaparin regimen for prevention of venous thromboembolism after knee arthroplasty surgery

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP110418

Dabigatran etexilate versus enoxaparin for prevention of venous thromboembolism after total hip replacement: a randomised, double-blind, non-inferiority trial.

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP110418

Oral dabigatran etexilate vs. subcutaneous enoxaparin for the prevention of venous thromboembolism after total knee replacement: the RE-MODEL randomized trial.

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP110418

Efficacy and safety of dabigatran etexilate for the prevention of venous thromboembolism following total hip or knee arthroplasty. A meta-analysis.

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP110418

Rivaroxaban-once daily, oral, direct factor Xa inhibition compared with vitamin K antagonism for prevention of stroke and Embolism Trial in Atrial Fibrillation: rationale and design of the ROCKET AF study

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP110418

Ximelagatran vs warfarin for stroke prevention in patients with nonvalvular atrial fibrillation: a randomized trial

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP110418

Stroke prevention with the oral direct thrombin inhibitor ximelagatran compared with warfarin in patients with non-valvular atrial fibrillation (SPORTIF III): randomised controlled trial

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP110418

Dabigatran versus warfarin in the treatment of acute venous thromboembolism

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP110418

Clopidogrel plus aspirin versus oral anticoagulation for atrial fibrillation in the Atrial fibrillation Clopidogrel Trial with Irbesartan for prevention of Vascular Events (ACTIVE W): a randomised controlled trial

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP110418

Antithrombotic therapy in atrial fibrillation: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition).

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP110418

Rivaroxaban versus placebo in patients with acute coronary syndromes (ATLAS ACS-TIMI 46): a randomised, double-blind, phase II trial.

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP110418

Rationale and design of the Anti-Xa therapy to lower cardiovascular events in addition to standard therapy in subjects with acute coronary syndrome-thrombolysis in myocardial infarction 51 (ATLAS-ACS 2 TIMI 51) trial: a randomized, double-blind, pla

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP110418

Treatment of Proximal Deep-Vein Thrombosis With the Oral Direct Factor Xa Inhibitor Rivaroxaban (BAY 59-7939): The ODIXa-DVT (Oral Direct Factor Xa Inhibitor BAY 59-7939 in Patients With Acute Symptomatic Deep-Vein Thrombosis) Study

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP110418

A dose-ranging study evaluating once-daily oral administration of the factor Xa inhibitor rivaroxaban in the treatment of patients with acute symptomatic deep vein thrombosis: the Einstein-DVT Dose-Ranging Study

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP110418

Oral rivaroxaban for symptomatic venous thromboembolism

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP110418

Extended-duration rivaroxaban thromboprophylaxis in acutely ill medical patients: MAGELLAN study protocol

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP110418

31 March 2020

Identifiers

DOI

10.2146/AJHP110418

1 reference

27 August 2017

1 reference